| Literature DB >> 21575135 |
Lia M Godinho1, Isabel de Sá-Nogueira.
Abstract
AraL from Bacillus subtilis is a member of the ubiquitous haloalkanoate dehalogenase superfamily. The araL gene has been cloned, over-expressed in Escherichia coli and its product purified to homogeneity. The enzyme displays phosphatase activity, which is optimal at neutral pH (7.0) and 65 °C. Substrate screening and kinetic analysis showed AraL to have low specificity and catalytic activity towards several sugar phosphates, which are metabolic intermediates of the glycolytic and pentose phosphate pathways. On the basis of substrate specificity and gene context within the arabinose metabolic operon, a putative physiological role of AraL in the detoxification of accidental accumulation of phosphorylated metabolites has been proposed. The ability of AraL to catabolize several related secondary metabolites requires regulation at the genetic level. In the present study, using site-directed mutagenesis, we show that the production of AraL is regulated by a structure in the translation initiation region of the mRNA, which most probably blocks access to the ribosome-binding site, preventing protein synthesis. Members of haloalkanoate dehalogenase subfamily IIA and IIB are characterized by a broad-range and overlapping specificity anticipating the need for regulation at the genetic level. We provide evidence for the existence of a genetic regulatory mechanism controlling the production of AraL.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21575135 PMCID: PMC3207120 DOI: 10.1111/j.1742-4658.2011.08177.x
Source DB: PubMed Journal: FEBS J ISSN: 1742-464X Impact factor: 5.542
Fig. 1Schematic representation of the araL genomic context in B. subtilis. White arrows pointing in the direction of transcription represent the genes in the arabinose operon, araABDLMNPQ-abfA. The araL gene is highlighted in grey and the promoter of the transcriptional unit is depicted by a black arrow. Depicted below the araABDLMNPQ-abfA is the in-frame deletion generated by allelic replacement ΔaraL. Above is displayed the coding sequence of the 5′-end of the araL gene. The putative ribosome-binding site, rbs, is underlined. The 5′-end of the araL gene present in the different constructs pLG5, pLG11, pLG12 and pLG13, is indicated by an arrow above the sequence. Mutations introduced in the construction of pLG11, pLG13 and pLG26 are indicated below the DNA sequence and the corresponding modification in the primary sequence of AraL is depicted above.
Fig. 2Alignment of AraL with other pNPPases members of the HAD superfamily (subfamily IIA). The amino acid sequences of AraL from B. subtilis (P94526), NagD from E. coli (P0AF24), the pNPPases from S. cerevisiae (P19881), Sz. pombe (Q00472) and P. falciparum (A5PGW7) were aligned using clustal w2 [41]. Similar (‘.’ and ‘:’) and identical (‘*’) amino acids are indicated. Gaps in the amino acid sequences inserted to optimize alignment are indicated by a dash (–). The motifs I, II, III and IV of the HAD superfamily and the cap domain C2 are boxed. Open arrowheads point to the catalytic residues in motifs I–IV. Identical residues in all five sequences, and identical residues in at least three sequences, are highlighted in dark and light grey, respectively.
Plasmids, oligonucleotides, and E. coli and B. subtilis strains used in the present study. Arrows indicate transformation and point from the donor DNA to the recipient strain. The restriction sites used are underlined, as are single-nucleotide point mutations
| Plasmid, strain or oligonucleotide | Relevant construction, genotype or sequence (5′- to 3′) | Source or Reference |
|---|---|---|
| Plasmids | ||
| pET30a | Expression vector allowing N- or C-terminal His6 tag insertion; T7 promoter, | Novagen |
| pMAD | Plasmid used for allelic replacement in Gram-positive bacteria, | [ |
| pAC5 | Plasmid used for generation of | [ |
| pLG5 | Present study | |
| pLG10 | pMAD derivative with an in frame deletion Δ | Present study |
| pLG11 | Present study | |
| pLG12 | Present study | |
| pLG13 | A pLG12 derivative with a mutation in the | Present study |
| pLG25 | A pAC5 derivative that contains a translational fusion of | Present study |
| pLG26 | A pLG25 derivative with a mutation in the | Present study |
| XL1 blue | ( | Stratagene |
| DH5α | Gibco-BRL | |
| BL21(DE3)pLysS | F− | [ |
| 168T+ | Prototroph | [ |
| IQB832 | Δ | pLG10→168T+ |
| IQB215 | Δ | [ |
| IQB847 | pLG25→168T+ | |
| IQB848 | Δ | pLG25→IQB215 |
| IQB849 | pLG26→168T+ | |
| IQB851 | pAC5→168T+ | |
| IQB853 | pLG27→168T+ | |
| IQB855 | pLG28→168T+ | |
| IQB857 | pLG29→168T+ | |
| Oligonucleotides | ||
| ARA28 | CCTATT | |
| ARA253 | TAACCCCAA | |
| ARA358 | CTGCTGTAATAATGGGTAGAAGG | |
| ARA439 | GGAATTC | |
| ARA440 | TATTTA | |
| ARA444 | CG | |
| ARA451 | GAATTCATAAAG | |
| ARA456 | CGGCGCGT | |
| ARA457 | TGATACG | |
| ARA458 | CTCAGCCAATTTGGTTACATCCTTGTCCAAGTCAATCAGAATGCCAGCCGGTGCCAC | |
| ARA459 | GTGTCACCGGCTGGCATTCTGATTGACTTGGACAAGGATGTAACCAAATTGGCTGAG | |
| ARA460 | CGT | |
| ARA477 | AATCAGAATG | |
| ARA486 | CGGCTG | |
| ARA487 | CAATCAGAATGTC | |
| ARA509 | CC AGT CAT GAT A | |
| ARA510 | CGG TGA CAC AGG C | |
| ARA514 | TAATACGCATTTGCTC CGT GTT TTC GTC ATA AAA TAA AAC GCT TTC AAA TAC | |
| ARA515 | GTATTTGAAAGCGTTTTATTTTATGACGAA AAC ACG GAG CAA ATG CGT ATT A | |
| ARA516 | CAC CAC GCT CAT CGA TAA TTT CAC C | |
| ARA549 | GGC CAG TCA TGA TA | |
| ARA550 | GGT GAC ACA GGC | |
| ARA551 | GCA AAT GC | |
| ARA552 | GAC ACA GGC | |
| ARA553 | CGG AGC AAA TGC T | |
| ARA554 | GAC TGG CCA TAA T | |
Fig. 3Overproduction and purification of recombinant AraL-His6. (A) Analysis of the soluble (S) and insoluble (P) protein fraction (20 μg of total protein) of induced cultures of E. coli Bl21(DE3) pLysS harboring pET30a (control) and pLG11 (AraL-His6). (B) Analysis of different fractions of purified recombinant AraL eluted with 300 mm imidazole. The proteins were separated by SDS/PAGE 12.5% gels and stained with Coomassie blue. A white arrowhead indicates AraL-His6. The size (kDa) of the broad-range molecular mass markers (Bio-Rad Laboratories) is indicated.
Fig. 4Effect of pH, temperature and co-factor concentration on AraL activity. Enzyme activity was determined using pNPP as substrate, at 65 °C, pH 7, and 15 mm MgCl2, unless stated otherwise. The results represent the mean of three independent experiments.
Kinetic constants for AraL against various substrates. Assays were performed at pH 7 and 37 °C, as described in the Experimental procedures. The results are the mean ± SD of triplicates. Substrates tested for which no activity was detected were: ATP, ADP, AMP, ribose 5-phosphate, glycerol 3-phosphate, pyridoxal 5-phosphate and thiamine monophosphate
| Substrate | |||
|---|---|---|---|
| 29.14 ± 4.87 | 2.75 ± 0.26 | 0.943 × 102 | |
| Glucose 6-phosphate | 24.96 ± 4.08 | 2.49 ± 0.26 | 0.998 × 102 |
| 27.36 ± 1.8 | 2.92 ± 0.10 | 1.06 × 102 | |
| Fructose 6-phosphate | 34.89 ± 4.51 | 2.817 ± 0.22 | 0.807 × 102 |
| Fructose 1,6-bisphosphate | 40.78 ± 11.40 | 1.49 ± 0.26 | 0.365 × 102 |
| Galactose 1-phosphate | 40.74 ± 6.03 | 4.28 ± 0.40 | 1.02 × 102 |
| 50.00 ± 23.32 | 0.012 ± 0.0006 | 0.24 |
Fig. 5Site-directed mutagenesis at the 5′-end of the araL gene and overproduction of recombinant AraL-His6. (A) The secondary structure of the araL mRNA in pLG12 (left) and pLG13 (right), which bears a single nucleotide change. An arrowhead highlights the mutated nucleotide located at the beginning of the araL coding region. The ribosome-binding site, rbs, and the initiation codon (ATG) are boxed. The position relative to the transcription start site is indicated. The free energy of the two secondary structures, calculated by dnasis, version 3.7 (Hitachi Software Engineering Co. Ltd, Tokyo, Japan), is shown. (B) Overproduction of recombinant AraL-His6. Analysis of the soluble (S) and insoluble (P) protein fraction (20 μg of total protein) of induced cultures of E. coli Bl21(DE3) pLysS harboring pLG12 (AraL-His6) and pLG113 (AraL-His6 G→A). The proteins were separated by SDS/PAGE 12.5% gels and stained with Coomassie blue. A white arrowhead indicates AraL-His6. The sizes (kDa) of the broad-range molecular mass markers (Bio-Rad Laboratories) are indicated.
Fig. 6Regulation of araL in B. subtilis. (A) Site-directed mutagenesis at the 5′-end of the araL gene. The secondary structure of the araABDLMNPQ-abfA mRNA at the 5′-end of the araL coding region is depicted. An arrow highlights the mutated nucleotide (circled) located at the beginning of the araL coding region. The ribosome-binding site, rbs, is boxed. (B) Expression from the wild-type and mutant araL′-′lacZ translational fusions. The B. subtilis strains IQB847 (Para-araL′-lacZ), IQB849 [Para-araL′ (C→A)-′lacZ], IQB857 [Para-araL′ (C→A and G→T)-′lacZ], IQB855 [Para-araL′ (C→G)-′lacZ] and IQB853 [Para-araL′ (C→G and G→C)-′lacZ] were grown on C minimal medium supplemented with casein hydrolysate in the absence (non-induced) or presence (induced) of arabinose. Samples were analyzed 2 h after induction. The levels of accumulated β-galactosidase activity represent the mean ± SD of three independent experiments, each performed in triplicate. A schematic representation of the translation fusion is depicted and the point mutations in the stem-loop structure are indicated by an asterisk. The free energy of the wild-type (WT) and mutated secondary structures, calculated by dnasis, version 3.7 (Hitachi Software Engineering Co. Ltd), are shown.